Cao Ying, Deng You, Wang Jingjing, Zhao Hong, Zhang Jingyu, Xie Wen
Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, No. 8, Jingshun East Street, Chaoyang District, Beijing 100015, China.
Ther Adv Chronic Dis. 2021 Nov 9;12:20406223211048649. doi: 10.1177/20406223211048649. eCollection 2021.
The aim of this study was to evaluate the association between nonalcoholic fatty liver disease (NAFLD) and NAFLD with different comorbidities and risk of chronic kidney disease (CKD) and abnormal albuminuria.
A total of 3872 Chinese individuals excluding those with hepatitis B or C infection and absence of alcohol abuse were included in the study. NAFLD was diagnosed by abdominal ultrasonography. The liver fibrosis was assessed by NAFLD fibrosis score (NFS) and fibrosis-4 index (FIB-4). CKD was defined as an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m and/or abnormal albuminuria (urinary albumin-to-creatinine ratio ⩾ 3 mg/mmol). The logistic regression analysis was performed to examine the association between NAFLD and NAFLD with different comorbidities and risk of CKD.
The prevalence of CKD and abnormal albuminuria was higher in individuals with NAFLD than in those without NAFLD (15.8% vs 11.9%, < 0.001; 14.8% vs 11.0%, < 0.001). Logistic regression analysis demonstrated that NAFLD was risk factor of CKD. Notably, after adjustment for sex, age, and DM, NAFLD was associated with 1.31-fold higher risk of prevalent CKD ⩾ 1 ( < 0.05). NAFLD individuals with elder age, DM, obesity, hypertension, MetS, and advanced liver fibrosis had higher risks of both prevalent CKD and abnormal albuminuria than those without comorbidities.
NAFLD and NAFLD with traditional comorbidities are strongly associated with risk of prevalence of CKD and abnormal albuminuria. Patients with NAFLD especially those with coexisting comorbidities were recommended to carefully access the development of CKD.
本研究旨在评估非酒精性脂肪性肝病(NAFLD)以及合并不同疾病的NAFLD与慢性肾脏病(CKD)及蛋白尿异常风险之间的关联。
本研究共纳入3872名中国个体,排除乙肝或丙肝感染以及无酒精滥用者。通过腹部超声诊断NAFLD。采用NAFLD纤维化评分(NFS)和纤维化-4指数(FIB-4)评估肝纤维化。CKD定义为估计肾小球滤过率(eGFR)<60 ml/min/1.73 m²和/或蛋白尿异常(尿白蛋白与肌酐比值≥3 mg/mmol)。进行逻辑回归分析以检验NAFLD以及合并不同疾病的NAFLD与CKD风险之间的关联。
NAFLD患者中CKD和蛋白尿异常的患病率高于无NAFLD者(15.8%对11.9%,P<0.001;14.8%对11.0%,P<0.001)。逻辑回归分析表明NAFLD是CKD的危险因素。值得注意的是,在调整性别、年龄和糖尿病后,NAFLD与CKD≥1期的患病风险高1.31倍相关(P<0.05)。与无合并症的NAFLD患者相比,年龄较大、患有糖尿病、肥胖、高血压、代谢综合征和晚期肝纤维化的NAFLD患者发生CKD和蛋白尿异常的风险更高。
NAFLD以及合并传统合并症的NAFLD与CKD患病率和蛋白尿异常风险密切相关。建议NAFLD患者,尤其是合并其他疾病的患者,仔细监测CKD的发展。